CoChat

A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis

Open access

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

Clear-cell carcinomas (CCCs) are a histological group of highly aggressive malignancies commonly originating in the kidney and ovary. CCCs are distinguished by aberrant lipid and glycogen accumulation and are refractory to a broad range of anti-cancer therapies. Here we identify an intrinsic vulnerability to ferroptosis associated with the unique metabolic state in CCCs. This vulnerability transcends lineage and genetic landscape, and can be exploited by inhibiting glutathione peroxidase 4 (GPX4) with small-molecules. Using CRISPR screening and lipidomic profiling, we identify the hypoxia-inducible factor (HIF) pathway as a driver of this vulnerability. In renal CCCs, HIF-2α selectively enriches polyunsaturated lipids, the rate-limiting substrates for lipid peroxidation, by activating the expression of hypoxia-inducible, lipid droplet-associated protein (HILPDA). Our study suggests targeting GPX4 as a therapeutic opportunity in CCCs, and highlights that therapeutic approaches can be identified on the basis of cell states manifested by morphological and metabolic features in hard-to-treat cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09277-9

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clear-cell carcinoma cells are intrinsically sensitive to GPX4 inhibition-induced ferroptosis. a Volcano-plot showing compound sensitivity comparison by normalized area-under-curve (AUC) values between clear-cell carcinoma (CCC) cells (n = 26) and other solid tumor cancer cell lines (sCCL) (n = 634) in CTRP. Cpds, compounds. b Chemical structures of GPX4 inhibitors ML210, RSL3, and ML162. c Scatterplot of AUCs for ML210 in sCCL (blue), CCC (red) or cancer cell lines from each tissue. Tissue types are ordered by the average AUC values. Abbreviations: CNS, central nervous system; UAT, upper aerodigestive tract; a_ganglia, autonomic ganglia. Mann–Whitney–Wilcoxon test, ****p < 0.0001. d Viability curves for the indicated cells treated with ML210 or RSL. n = 4. Representative plot of experiments repeated three times. e Viability curves for the indicated cells treated with ML210 or RSL3 plus indicated DMSO, liproxstatin-1 (Lip-1) or ferrostatin-1 (Fer-1). Representative plot of experiments repeated three times. f Fluorescent images of BODIPY-C11 stained 786-O, 769-P, and BFTC909 cells treated with ML210 plus DMSO or Lip-1 for the indicated time periods. Scale bars: 10 µm. g Immunoblot showing GPX4 protein levels in GPX4+/+ 786-O or GPX4−/− clones 3A2 and 3A7. h Viability curves for WT 786-O, 3A2, and 3A7 over a 2.5-day time course after Fer-1 removal. Representative plot of experiments repeated three times. i Tumor volume measurements of subcutaneous xenografts of WT 786-O or GPX4−/− 3A2 cells (n = 10 mice, two tumors per mouse). GPX4−/− tumor-bearing mice were divided to a Lip-1 treated group and a vehicle-treated group. Treatment lasted for the first 10 days. Two-tailed t-test, ***p < 0.001, ****p < 0.0001. j Immunoblot showing HIF-2α protein levels in primary human ccRCC cell lines CCLF_KIPA_0001_T, CCLF_KIPA_0002_T, and normal renal-cell culture CCLF_KIPA_0001_N matched with CCLF_KIPA_0001_T. k Viability curves for indicated cell lines treated with ML210 or RSL3 plus DMSO or 0.5 µM of Lip-1. n = 4. Representative plot of experiments repeated twice. l Viability curves for ovarian clear-cell carcinoma (OCCC) cell lines ES-2, OVISE, and TOV21G, and high-grade serous carcinoma (HGSC) line OV-90 treated with ML210 (left) or RSL3 (right). n = 4. Representative plot of experiments repeated twice. Error bars: ±s.d. β-Actin was used as loading controls for immunoblots
Fig. 1 Clear-cell carcinoma cells are intrinsically sensitive to GPX4 inhibition-induced ferroptosis. a Volcano-plot showing compound sensitivity comparison by normalized area-under-curve (AUC) values between clear-cell carcinoma (CCC) cells (n = 26) and other solid tumor cancer cell lines (sCCL) (n = 634) in CTRP. Cpds, compounds. b Chemical structures of GPX4 inhibitors ML210, RSL3, and ML162. c Scatterplot of AUCs for ML210 in sCCL (blue), CCC (red) or cancer cell lines from each tissue. Tissue types are ordered by the average AUC values. Abbreviations: CNS, central nervous system; UAT, upper aerodigestive tract; a_ganglia, autonomic ganglia. Mann–Whitney–Wilcoxon test, ****p < 0.0001. d Viability curves for the indicated cells treated with ML210 or RSL. n = 4. Representative plot of experiments repeated three times. e Viability curves for the indicated cells treated with ML210 or RSL3 plus indicated DMSO, liproxstatin-1 (Lip-1) or ferrostatin-1 (Fer-1). Representative plot of experiments repeated three times. f Fluorescent images of BODIPY-C11 stained 786-O, 769-P, and BFTC909 cells treated with ML210 plus DMSO or Lip-1 for the indicated time periods. Scale bars: 10 µm. g Immunoblot showing GPX4 protein levels in GPX4+/+ 786-O or GPX4−/− clones 3A2 and 3A7. h Viability curves for WT 786-O, 3A2, and 3A7 over a 2.5-day time course after Fer-1 removal. Representative plot of experiments repeated three times. i Tumor volume measurements of subcutaneous xenografts of WT 786-O or GPX4−/− 3A2 cells (n = 10 mice, two tumors per mouse). GPX4−/− tumor-bearing mice were divided to a Lip-1 treated group and a vehicle-treated group. Treatment lasted for the first 10 days. Two-tailed t-test, ***p < 0.001, ****p < 0.0001. j Immunoblot showing HIF-2α protein levels in primary human ccRCC cell lines CCLF_KIPA_0001_T, CCLF_KIPA_0002_T, and normal renal-cell culture CCLF_KIPA_0001_N matched with CCLF_KIPA_0001_T. k Viability curves for indicated cell lines treated with ML210 or RSL3 plus DMSO or 0.5 µM of Lip-1. n = 4. Representative plot of experiments repeated twice. l Viability curves for ovarian clear-cell carcinoma (OCCC) cell lines ES-2, OVISE, and TOV21G, and high-grade serous carcinoma (HGSC) line OV-90 treated with ML210 (left) or RSL3 (right). n = 4. Representative plot of experiments repeated twice. Error bars: ±s.d. β-Actin was used as loading controls for immunoblotsCC BY · PubMed Central
Fig. 2 Genome-wide CRISPR screen identifies HIF-2α as a driver of ferroptosis susceptibility. a Experimental scheme describing the genome-wide CRISPR resistance screening to identify mediators of ML210 sensitivity in 786-O cells. b Volcano plot highlighting top enriched CRISPR hits in 786-O cells treated with ML210 for 4, 6 or 8 days. Red genes, HIF pathway genes. Purple genes, representative known ferroptosis regulators. c Relative AUC values of the Cas9/sgRNA (CRISPR) or shRNA (RNAi) transfected 786-O cells treated with a 7-point, 2-fold dilution series of ML210. The viability of cells expressing each sgRNA/shRNA (blue dots) was normalized to the respective DMSO-treated condition. AUC values were normalized to 1 as the total area-under-curve for the concentration range of ML210. d Immunoblot showing the HIF-2α/HIF-1β protein levels in control (sgNC) or EPAS1-targeting sgRNA-expressing 786-O-Cas9 and 769-P-Cas9 cells. e Viability curves of control (sgNC) or EPAS1-targeting sgRNA-expressing 786-O-Cas9 and 769-P-Cas9 cells treated with indicated concentrations of ML210 or RSL3. Representative plot of experiments repeated three times. f Immunoblot showing HIF-2α and HIF-1β protein levels in wildtype (WT, EPAS1+/+) 786-O cells and four EPAS1−/− single-cell clones generated by CRISPR/Cas9. g Viability curves for WT EPAS1+/+ 786-O or EPAS1−/− clones treated with indicated concentrations of ML210 or RSL3. Representative plot of experiments repeated three times. h Viability curves for EPAS1−/− 786-O single-cell clones 1D7 and 1E3 expressing vector or EPAS1-GFP, then treated with indicated concentrations of ML210 or RSL3. Representative plot of experiments repeated three times. β-Actin was used as loading controls in immunoblots
Fig. 2 Genome-wide CRISPR screen identifies HIF-2α as a driver of ferroptosis susceptibility. a Experimental scheme describing the genome-wide CRISPR resistance screening to identify mediators of ML210 sensitivity in 786-O cells. b Volcano plot highlighting top enriched CRISPR hits in 786-O cells treated with ML210 for 4, 6 or 8 days. Red genes, HIF pathway genes. Purple genes, representative known ferroptosis regulators. c Relative AUC values of the Cas9/sgRNA (CRISPR) or shRNA (RNAi) transfected 786-O cells treated with a 7-point, 2-fold dilution series of ML210. The viability of cells expressing each sgRNA/shRNA (blue dots) was normalized to the respective DMSO-treated condition. AUC values were normalized to 1 as the total area-under-curve for the concentration range of ML210. d Immunoblot showing the HIF-2α/HIF-1β protein levels in control (sgNC) or EPAS1-targeting sgRNA-expressing 786-O-Cas9 and 769-P-Cas9 cells. e Viability curves of control (sgNC) or EPAS1-targeting sgRNA-expressing 786-O-Cas9 and 769-P-Cas9 cells treated with indicated concentrations of ML210 or RSL3. Representative plot of experiments repeated three times. f Immunoblot showing HIF-2α and HIF-1β protein levels in wildtype (WT, EPAS1+/+) 786-O cells and four EPAS1−/− single-cell clones generated by CRISPR/Cas9. g Viability curves for WT EPAS1+/+ 786-O or EPAS1−/− clones treated with indicated concentrations of ML210 or RSL3. Representative plot of experiments repeated three times. h Viability curves for EPAS1−/− 786-O single-cell clones 1D7 and 1E3 expressing vector or EPAS1-GFP, then treated with indicated concentrations of ML210 or RSL3. Representative plot of experiments repeated three times. β-Actin was used as loading controls in immunoblotsCC BY · PubMed Central
Fig. 3 HIF-2α selectively enriches polyunsaturated lipids. a Heatmap representing the relative lipid abundances in indicated cell lines. The abundance of each lipid species is normalized to the mean of that in the EPAS1+/+ 786-O WT cells and the ratios are log2 transformed. The lipids are grouped by classes, and within each class, the lipid species are ordered first with increasing carbon number, then with increasing unsaturation levels. Abbreviations: CE, cholesterol ester; Cer, ceramide; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; ePC, (vinyl ether-linked) PC-plasmalogen; ePE, (vinyl ether-linked) PE-plasmalogen; PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin. Blue: down-regulated relative to the WT cells, red: upregulated relative to the WT cells. The wave-like pattern in the TAG class corresponds to the more significant losses in the polyunsaturated fatty acyl (PUFA)-TAGs than saturated/monounsaturated fatty acyl (SFA/MUFA)-TAGs in response to HIF-2α-depletion. S, ferroptosis-sensitive; (R), ferroptosis-resistant. b Volcano plots showing the changes in TAGs grouped as PUFA-TAGs (red fill) and SFA/MUFA-TAGs (white fill) between the indicated cell lines. n = 3, two-tailed t-test. c Volcano plots showing changes in PE and ePE lipids grouped as PUFA-PE/ePEs (red fill) and SFA/MUFA-PE/ePEs (white fill) between the indicated cell lines. d Bar graph representing the relative abundances of the indicated PUFA-PE/ePE lipids in the labeled groups. Log2 fold changes relative to 786-O WT cells are presented for each condition. n = 3, error bars: ±s.d. e Bar graph representing the relative abundances of the indicated free fatty acids grouped as PUFAs or SFA/MUFAs in the indicated conditions. nd, not-detectable under the experimental condition. n = 3, error bars: ±s.d. f Viability curves of 786-O-Cas9 and 769-P-Cas9 cells expressing control (sgNC) or EPAS1-targeting sgRNAs, first treated with BSA or PUFA (arachidonic acid, C20:4) for 3 days, then treated with indicated concentrations of ML210 or RSL3 for 48 h. Representative plot of experiments repeated twice. g The ratios between PUFA-PE/ePE and total PE/ePE (left), and between PUFA-PC/ePC and total PC/ePCs in ccRCC tumor samples (n = 49; red) and the matched normal tissues (n = 49; gray) from previously reported lipidomics datasets. Student’s T-test, ***p < 0.001
Fig. 3 HIF-2α selectively enriches polyunsaturated lipids. a Heatmap representing the relative lipid abundances in indicated cell lines. The abundance of each lipid species is normalized to the mean of that in the EPAS1+/+ 786-O WT cells and the ratios are log2 transformed. The lipids are grouped by classes, and within each class, the lipid species are ordered first with increasing carbon number, then with increasing unsaturation levels. Abbreviations: CE, cholesterol ester; Cer, ceramide; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; ePC, (vinyl ether-linked) PC-plasmalogen; ePE, (vinyl ether-linked) PE-plasmalogen; PI, phosphatidylinositol; PS, phosphatidylserine; SM, sphingomyelin. Blue: down-regulated relative to the WT cells, red: upregulated relative to the WT cells. The wave-like pattern in the TAG class corresponds to the more significant losses in the polyunsaturated fatty acyl (PUFA)-TAGs than saturated/monounsaturated fatty acyl (SFA/MUFA)-TAGs in response to HIF-2α-depletion. S, ferroptosis-sensitive; (R), ferroptosis-resistant. b Volcano plots showing the changes in TAGs grouped as PUFA-TAGs (red fill) and SFA/MUFA-TAGs (white fill) between the indicated cell lines. n = 3, two-tailed t-test. c Volcano plots showing changes in PE and ePE lipids grouped as PUFA-PE/ePEs (red fill) and SFA/MUFA-PE/ePEs (white fill) between the indicated cell lines. d Bar graph representing the relative abundances of the indicated PUFA-PE/ePE lipids in the labeled groups. Log2 fold changes relative to 786-O WT cells are presented for each condition. n = 3, error bars: ±s.d. e Bar graph representing the relative abundances of the indicated free fatty acids grouped as PUFAs or SFA/MUFAs in the indicated conditions. nd, not-detectable under the experimental condition. n = 3, error bars: ±s.d. f Viability curves of 786-O-Cas9 and 769-P-Cas9 cells expressing control (sgNC) or EPAS1-targeting sgRNAs, first treated with BSA or PUFA (arachidonic acid, C20:4) for 3 days, then treated with indicated concentrations of ML210 or RSL3 for 48 h. Representative plot of experiments repeated twice. g The ratios between PUFA-PE/ePE and total PE/ePE (left), and between PUFA-PC/ePC and total PC/ePCs in ccRCC tumor samples (n = 49; red) and the matched normal tissues (n = 49; gray) from previously reported lipidomics datasets. Student’s T-test, ***p < 0.001CC BY · PubMed Central
Fig. 4 HILPDA enriches polyunsaturated lipids and promotes ferroptosis sensitivity downstream of HIF-2α. a Scheme summarizing the experimental strategy for identifying the HIF-2α target genes mediating ferroptosis susceptibility in 786-O cells. b Heatmap showing the RNA-Seq analysis of WT 786-O cells and three EPAS1−/− clones (1D1, 1D7, and 1E3). HIF-2α-dependent known lipid metabolism genes are highlighted. c Viability curves of cDNA screening results in EPAS1−/− clones treated with a 7-point, 2-fold dilution series of ML210 or RSL3. Viability is relative to that of each cell line under zero ML210 or RSL3 treatment, respectively. n = 4, error bars are omitted for visual clarity. d Viability curves of HILPDA, G0S2, or EGFP-overexpressing EPAS1−/− 1D1 and 1D7 cells treated with ML210 or RSL3 for 48 h. Viability is relative to the respective DMSO-treated conditions. n = 4, Representative plot of experiments repeated three times. e qRT-PCR analysis of HILPDA mRNA levels in 786-O cells expressing shNC or shHILPDAs. B2M was used as an internal control. n = 3. Student’s T-test. *p < 0.05. f Immunoblot analysis of HILPDA protein levels in 786-O cells expressing shNC or shHILPDAs. β-Actin was used as a loading control. g Viability curves for 786-O cells expressing shNC or two most effective shHILPDAs under indicated concentrations of ML210 or RSL3. Viability is relative to the DMSO-treated conditions, n = 4. Representative plot of experiments repeated three times. h Volcano plots showing the changes in each TAG (left panels) and PE/ePE (right panels) species grouped as PUFA-containing (red fill) or SFA/MUFA-only (white fill) lipids between the indicated cell lines. n = 3. i Bar graph showing the relative abundances of the PUFA-PE/ePEs in the conditions tested. n = 3. S, ferroptosis-sensitive; (R), ferroptosis-resistant. j Lipid droplet abundances analyzed by flow cytometry quantitation of BODIPY-493/503 signal in 1D1 and 1D7 EPAS1−/− cells expressing exogenous EGFP, HILPDA, G0S2 or PLIN2. Representative plot of experiments repeated three times. k Scheme summarizing the molecular network driving the intrinsic GPX4 dependency and ferroptosis susceptibility in clear-cell carcinomas. Abbreviations: PUFA, polyunsaturated fatty acids, e.g. arachidonic acid (C20:4); TAG, triacylglycerols; PE, phosphatidylethanolamine; ePE, vinyl ether-linked PE-plasmalogens. Metabolites highlighted in red indicate promoters of ferroptosis susceptibility. Error bars: ±s.d
Fig. 4 HILPDA enriches polyunsaturated lipids and promotes ferroptosis sensitivity downstream of HIF-2α. a Scheme summarizing the experimental strategy for identifying the HIF-2α target genes mediating ferroptosis susceptibility in 786-O cells. b Heatmap showing the RNA-Seq analysis of WT 786-O cells and three EPAS1−/− clones (1D1, 1D7, and 1E3). HIF-2α-dependent known lipid metabolism genes are highlighted. c Viability curves of cDNA screening results in EPAS1−/− clones treated with a 7-point, 2-fold dilution series of ML210 or RSL3. Viability is relative to that of each cell line under zero ML210 or RSL3 treatment, respectively. n = 4, error bars are omitted for visual clarity. d Viability curves of HILPDA, G0S2, or EGFP-overexpressing EPAS1−/− 1D1 and 1D7 cells treated with ML210 or RSL3 for 48 h. Viability is relative to the respective DMSO-treated conditions. n = 4, Representative plot of experiments repeated three times. e qRT-PCR analysis of HILPDA mRNA levels in 786-O cells expressing shNC or shHILPDAs. B2M was used as an internal control. n = 3. Student’s T-test. *p < 0.05. f Immunoblot analysis of HILPDA protein levels in 786-O cells expressing shNC or shHILPDAs. β-Actin was used as a loading control. g Viability curves for 786-O cells expressing shNC or two most effective shHILPDAs under indicated concentrations of ML210 or RSL3. Viability is relative to the DMSO-treated conditions, n = 4. Representative plot of experiments repeated three times. h Volcano plots showing the changes in each TAG (left panels) and PE/ePE (right panels) species grouped as PUFA-containing (red fill) or SFA/MUFA-only (white fill) lipids between the indicated cell lines. n = 3. i Bar graph showing the relative abundances of the PUFA-PE/ePEs in the conditions tested. n = 3. S, ferroptosis-sensitive; (R), ferroptosis-resistant. j Lipid droplet abundances analyzed by flow cytometry quantitation of BODIPY-493/503 signal in 1D1 and 1D7 EPAS1−/− cells expressing exogenous EGFP, HILPDA, G0S2 or PLIN2. Representative plot of experiments repeated three times. k Scheme summarizing the molecular network driving the intrinsic GPX4 dependency and ferroptosis susceptibility in clear-cell carcinomas. Abbreviations: PUFA, polyunsaturated fatty acids, e.g. arachidonic acid (C20:4); TAG, triacylglycerols; PE, phosphatidylethanolamine; ePE, vinyl ether-linked PE-plasmalogens. Metabolites highlighted in red indicate promoters of ferroptosis susceptibility. Error bars: ±s.dCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 952

Metadata

Authors
Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., Leshchiner, E. S., Viswanathan, V. S., Signoretti, S., Choueiri, T. K., Boehm, J. S., Wagner, B. K., Doench, J. G., Clish, C. B., Clemons, P. A., & Schreiber, S. L.
Affiliations
  • Broad Institute (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Schreiber, Stuart L.
Venue
Nature Communications
Published
2019-04-08
Volume
10
Issue
1
Pages
1617-1617
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2932111434
Cited by
887
References
72
Citations by year
2026: 94 · 2025: 141 · 2024: 163 · 2023: 166 · 2022: 144 · 2021: 98 · 2020: 69 · 2019: 11
FWCI
59.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Dana-Farber/Harvard Cancer Center (CA101942)
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (T32HL007627)
  • National Cancer Institute (U01CA217848, P50CA101942, CA101942)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK040561)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
clear cell carcinoma, ferroptosis, GPX4, HIF-2α, HILPDA, lipid peroxidation, polyunsaturated lipids, lipidomics, clear cell renal cell carcinoma, ovarian clear cell carcinoma, cancer cell states, metabolic vulnerability, hypoxia
MeSH terms
Phospholipid Hydroperoxide Glutathione Peroxidase, Endothelial PAS Domain-Containing Protein 1, Aged, Animals, Carcinoma, Renal Cell, Female, Glutathione Peroxidase, Humans, Iron, Kidney Neoplasms, Male, Mice, Nude, Middle Aged, Neoplasm Proteins, Lipid Peroxidation, Gene Expression Regulation, Neoplastic, Apoptosis, Gene Expression Profiling, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Gene Knockout Techniques, HEK293 Cells, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. https://app.cochat.ai/papers/10.1038/s41467-019-09277-9
The paper
Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., Leshchiner, E. S., Viswanathan, V. S., Signoretti, S., Choueiri, T. K., Boehm, J. S., Wagner, B. K., Doench, J. G., Clish, C. B., Clemons, P. A., & Schreiber, S. L. (2019). A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications. https://doi.org/10.1038/s41467-019-09277-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.